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Abstract: The pathophysiology of type 2 diabetes has been attributed to the classic triad 
of  decreased  insulin  secretion,  increased  insulin  resistance,  and  elevated  hepatic  glucose 
production.  Research  has  shown  additional  mechanisms,  including  incretin  deficiency  or 
resistance in the gastrointestinal tract. Liraglutide is a modified form of human glucagon-like 
peptide-1. Liraglutide was obtained by substitution of lysine 34 for arginine near the NH2 
terminus, and by addition of a C16 fatty acid at the ε-amino group of lysine (at position 26) using 
a γ-glutamic acid spacer. Liraglutide has demonstrated glucose-dependent insulin secretion, 
improvements in β-cell function, deceleration of gastric emptying, and promotion of early 
satiety leading to weight loss. Liraglutide has the potential to acquire an important role, not 
only in the treatment of type 2 diabetes, but also in preservation of β-cell function, weight loss, 
and prevention of chronic diabetic complications.
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Introduction
Type 2 diabetes mellitus (T2DM) is a major public health burden that poses 
management challenges in clinical practice.1 The core pathophysiology of T2DM 
has been   attributed to the classic triad of decreased insulin secretion, increased 
insulin resistance, and elevated hepatic glucose production. Research has shown that 
additional mechanisms, including those related to the fat cell (accelerated lipolysis), 
gastrointestinal tract (incretin deficiency/resistance), α-cell (hyperglucagonemia), 
kidney (increased glucose reabsorption), and the brain (insulin resistance), referred 
to as the “ominous octet”,2 are also involved.
Overt T2DM occurs only when β-cells fail (due to decreased mass or their 
  failure to recognize the hyperglycemic signal) and can no longer compensate for 
the increased insulin secretion required to maintain normoglycemia.3 Amelioration 
of the decline in β-cell function must be addressed to alter the progressive nature of 
the disease.4,5 Agents that may prevent deterioration of β-cell function or enhance 
endogenous insulin concentrations are much needed for the management of T2DM. 
Other pathophysiologic defects of T2DM that current therapeutic agents do not address 
include hyperglucagonemia, accelerated gastric emptying, and decrease or loss of the 
incretin effect.
It had been demonstrated that glucagon secretion in T2DM is not suppressed 
after a carbohydrate-rich meal.6,7 This results in an inability to suppress postprandial 
hepatic glucose production and excessive plasma glucose excursions. The rate of Drug Design, Development and Therapy 2010:4 submit your manuscript | www.dovepress.com
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gastric   emptying is a key determinant of postprandial 
glucose excursions and is often accelerated in people with 
diabetes.8,9
In T2DM, glucagon-like peptide-1 (GLP-1) concentrations 
are reduced in response to a meal, whereas glucose-dependent 
insulinotropic polypeptide concentrations are normal or 
increased. This observation suggests resistance to the actions 
of glucose-dependent insulinotropic polypeptide, making 
GLP-1 the favored potential therapeutic target.10,11
Many of the pathophysiologic disturbances that are 
present in T2DM can be corrected by incretin replacement 
with GLP-1. In response to the physiologic loss of incre-
tin activity associated with T2DM, administration of 
exogenous GLP-1 has been shown to lower both fasting 
and postprandial plasma glucose significantly.12,13 The main 
limitation in developing GLP-1 for the treatment of T2DM 
is its short half-life of less than two minutes. By removing 
two N-terminal amino acids, dipeptidyl peptidase-4 (DPP-4) 
rapidly inactivates GLP-1.14 The development of the GLP-1 
receptor agonists offers incretin-based therapies with built-in 
modifications to provide resistance to DPP-4 degradation.
Pharmacokinetics  
and pharmacology
Liraglutide (Victoza®; Novo Nordisk Inc, Bagsvaerd, 
Denmark) is a modified form of human GLP-1 (γ-L-
glutamyl[N-α-hexadenoyl]-Lys,26 Arg34-GLP-1 [7–37]). 
Native GLP-1 is a 30-amino acid peptide produced by 
cleavage of the transcription product of the preproglucagon 
gene.15 Liraglutide was obtained by substitution of lysine 
34 to arginine near the NH2 terminus, and by addition of 
a C16 fatty acid at the ε-amino group of lysine (at position 
26) using a γ-glutamic acid spacer, which allows noncovalent 
binding to albumin (see Figure 1).16 The resultant molecule 
shares 97% (36/37 amino acids) sequence identity with native 
human GLP-1.17 The high degree of homology of liraglutide 
to GLP-1 may in part explain the relatively low levels of 
antibodies produced in response to liraglutide. However, the 
clinical relevance of antibodies is not yet known.
Pharmacokinetic studies show that liraglutide, after 
  subcutaneous injection, has a time to maximum plasma 
concentration (Tmax) of 9–13 hours and a half-life (T1/2) of 
13 hours. The structural modifications of liraglutide are 
responsible for the prolonged half-life. Indeed, following 
  subcutaneous injection, the fatty acid chain allows   liraglutide 
to self-associate and form heptamers at the injection site 
depot. It is thought that the size of the heptamer and strong 
self-association are the most likely mechanisms by which 
delayed absorption of liraglutide from the subcutis is 
  facilitated.18 Once in the bloodstream, the fatty acid chain 
allows reversible binding to serum albumin, providing partial 
stability and resistance to metabolism by DDP-4 and reduces 
renal clearance, giving liraglutide a protracted mechanism 
of action.19
Liraglutide metabolism does not depend on one single 
organ for its elimination. About 89%–100% of intact 
  liraglutide is present in plasma, with only two minor 
  metabolites and no intact liraglutide detected in urine or 
feces,17 suggesting slow degradation into small peptides, 
amino acids, and fatty acid fragments eliminated through 
the liver or the kidney.20,21
To evaluate the effect of hepatic impairment on the 
pharmacokinetic properties of liraglutide, six patients 
with normal hepatic function and 18 patients with mild, 
  moderate, or severe hepatic impairment received a single 
dose of   subcutaneous liraglutide 0.75 mg.22 Liraglutide 
  bioavailability appeared to decrease with an increasing 
degree of hepatic impairment, with no significant differences 
in the safety parameters between the two groups.
The effect of injection site (abdomen, upper arm, and 
thigh) on the pharmacokinetic profile of liraglutide was 
investigated.23 It was found that based on the area under 
the concentration-time curve (AUC), the abdomen and 
thigh were equivalent. However, lower bioavailability was 
observed in the thigh compared with the abdomen. Although 
Tmax and T1/2 were similar between the injection sites, 
maximum concentration (Cmax) was lower in the thigh than 
in the abdomen. Based on these results, the differences in 
bioavailability were not considered clinically relevant, and 
the three injection sites can be used interchangeably. Age 
and gender pharmacokinetic equivalence of subcutaneous 
liraglutide 1 mg/day demonstrated that when adjusted for 
body weight, similarity was confirmed between young and 
elderly subjects, and no significant effect of gender was 
observed.24
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Liraglutide delays gastric emptying and could affect 
the absorption pattern of concomitant drugs. The effect of 
subcutaneous liraglutide 1.8 mg on the pharmacokinetic 
properties of atorvastatin 40 mg, griseofulvin 500 mg, 
lisinopril 20 mg, and digoxin 1 mg was evaluated in healthy 
subjects.25 The AUCs of griseofulvin and atorvastatin were 
equivalent in liraglutide-treated and placebo-treated sub-
jects. On the other hand, the AUCs of lisinopril and digoxin 
were decreased by 15% and 16%, respectively. The Cmax for 
atorvastatin, digoxin, and lisinopril was decreased and for 
griseofulvin was increased. Tmax for atorvastatin, digoxin, 
and lisinopril was also delayed, confirming a liraglutide-
induced shift in absorption kinetics. A similar study assessing 
the effects on acetaminophen after exposure to liraglutide23 
also demonstrated lower Cmax and delayed Tmax compared 
with placebo.
One of the first large single-center, randomized, double-
blind, sequential dose escalation (1.25 to 20.0 µg/kg single 
dose) study of 64 healthy nondiabetic men confirmed that 
liraglutide has a pharmacokinetic profile that is consistent 
with once-daily administration (Tmax 9–12 hours after dosing 
and T1/2 11–15 hours).26 Absorption of liraglutide was slow, 
with Cmax achieved between 9 and 12 hours after dosing. 
A frequently sampled intravenous glucose tolerance test 
(IVGTT) was performed and showed a statistically significant 
increase in insulin secretion (P = 0.0002), but there was no 
significant effect on glucagon levels. No significant effect 
was observed on glucose levels during the IVGTT, but there 
was a dose-dependent increase in the glucose disappearance 
constant. There were no reports of serious adverse events and 
all subjects completed the study. A higher number of adverse 
events were reported in subjects in active treatment versus 
placebo treatment, such as headache, dizziness, nausea, and 
vomiting. Whereas headache and dizziness occurred at the 
majority of dose levels, nausea and vomiting mainly occurred 
at 10–15 µg/kg. There was a tendency toward lower urine 
volumes at doses $12.5 µg/kg, but there was no overall 
significant difference in urine volumes 0–24 hours after dose 
administration between active and placebo treatment.
Another study in 30 healthy men with consecutive dose 
levels of liraglutide (1.25–12.5 µg/kg)19 showed similar 
results. There were dose-proportional increases in exposure 
(AUC and Cmax) with increasing doses. There were no statisti-
cally significant differences from placebo in 24-hour glucose 
and insulin profiles. Overall, there was a higher frequency 
of adverse events in the active-treated patients than in the 
placebo-treated subjects. Three subjects were withdrawn 
due to adverse events, dizziness, fever and pharyngitis, and 
nausea and diarrhea. There were no serious adverse events 
during the study. Combined urine volume data showed 
a   statistically significant reduction following a dose of 
  liraglutide compared with placebo.
In a dose-finding study in 24 healthy Japanese men 
who received three consecutive dose levels of liraglutide 
(15–25 µg/kg), the daily pharmacokinetic profiles after 
receiving the last dose showed dose-dependent increases 
in the AUC at 0–24 hours, Cmax, and minimum concentra-
tion. Elimination rate constant, volume of distribution, and 
clearance were not affected by dose.27 A similar profile was 
found when the drug was administered to T2DM patients 
once daily as a subcutaneous injection for one week.28 
Relatively high plasma concentrations of liraglutide were 
maintained throughout the 24-hour dosing period, demon-
strating that once-daily administration of liraglutide should 
be sufficient.
Mode of action
Liraglutide has demonstrated glucose-dependent insulin 
secretion, improvements in β-cell function, deceleration of 
gastric emptying, and promotion of early satiety leading to 
weight loss.29
The effects of liraglutide on β-cells in vitro and in 
  animal models were of particular interest. When mice with 
diabetes mellitus (db/db mice) were exposed to liraglutide, 
a significantly increased β-cell mass (P , 0.05) and β-cell 
proliferation rate (P , 0.001) were observed versus placebo 
exposure.30 The effect of liraglutide on β-cell mass was also 
noted in Zucker diabetic fatty rats.31 After six weeks of 
treatment, a higher total β-cell mass was observed in Zucker 
diabetic fatty rats treated with liraglutide than in those in the 
placebo group (P , 0.03). When normoglycemia was main-
tained in these animals, liraglutide did not cause expansion 
of β-cell mass. This may suggest that the influence of GLP-1 
agonism on β-cell mass dynamics in vivo may depend on 
the glycemic state.
Liraglutide was significantly better than native GLP-1 in 
inhibiting apoptosis in cells treated with either agent. 
  Particularly, liraglutide was able to inhibit cytokine-induced 
apoptosis in primary rat islet cells in a dose-dependent 
manner, and to reduce free fatty acid-induced apoptosis by 
approximately 50%.32
Furthermore, a recent study investigated the efficacy of 
liraglutide to prevent or delay diabetes in UC Davis T2DM 
rats, a model of polygenic obese T2DM.33 Liraglutide 
treatment delayed diabetes onset by 4.1 ± 0.8 months 
  compared with control (P , 0.0001) and by 1.3 ± 0.8 months Drug Design, Development and Therapy 2010:4 submit your manuscript | www.dovepress.com
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compared with energy-restricted animals (P , 0.05). Energy 
restriction and liraglutide treatment lowered fasting plasma 
glucose and glycosylated hemoglobin (HbA1C) compared 
with control. Liraglutide-treated animals demonstrated 
lower fasting plasma insulin, glucagon, and triglycerides 
compared with both control and energy-restricted animals. 
  Additionally, energy-restricted and liraglutide-treated 
  animals exhibited more normal islet morphology.
The effect of a single subcutaneous dose of liraglutide 
10 µg/kg on glycemic control was assessed in patients 
with T2DM.34 Liraglutide significantly reduced fasting 
plasma glucose compared with placebo (6.9 ± 1.0 versus 
8.1 ± 1.0 mmol/L, P , 0.01). In another study,   subcutaneous 
liraglutide 0.6 mg once daily35 improved fasting plasma 
glucose, and this effect was significant after the first week 
and persisted through eight weeks of treatment (P = 0.002 
versus placebo). There was also a significant decrease in 
HbA1C levels compared with placebo (−0.80%, P = 0.028). 
Liraglutide caused a moderate delay in the postprandial rate 
of gastric emptying and reduced the rate at which postpran-
dial plasma glucose appeared in the circulation.
A study in patients with T2DM showed that liraglutide 
increased β-cell function in the fasting state by 30%, by 
homeostasis model assessment for β function (HOMA-B).28 
The maximum β-cell secretory capacity was significantly 
higher after treatment with liraglutide compared with   placebo, 
and the proinsulin-to-insulin ratio was reduced by 40%–50%, 
an additional indication of improved β-cell   function. This 
resulted in a significant reduction by   approximately 20% 
in 24-hour glucose AUC and postprandial glucose after 
liraglutide injection. With liraglutide, insulin concentrations 
were significantly higher after an intravenous glucose bolus 
(first-phase insulin secretion, a 60% increase) and during 
steady-state hyperglycemia (second-phase insulin secretion, 
a 240% increase).36
Patients with T2DM were randomized to treatment 
with liraglutide 0.65, 1.25, or 1.9 mg/day or placebo to 
evaluate insulin secretion.37 After 14 weeks, first-phase 
insulin   secretion (measured by IVGTT) was significantly 
increased at the two highest doses of liraglutide by 118% 
and 103%, respectively. Second-phase insulin secretion 
was significantly increased only in the 1.25 mg/day group 
versus placebo. Arginine-stimulated insulin secretion dur-
ing a hyperglycemic clamp test also increased significantly 
at the two highest dose levels versus placebo, by 114% and 
94%, respectively.
It has been demonstrated that treatment with   liraglutide, 
at a dose of 1.8 mg daily, significantly decreased the 
mean energy intake by 18% during an ad libitum meal 
(∼850 kJ).38 A modest effect on appetite sensation has also 
been reported.
Liraglutide has demonstrated some blood pressure-
  lowering effects. In a 14-week study, a significant 5–8 mmHg 
reduction in systolic blood pressure with different doses 
of liraglutide was seen, with no change in diastolic blood 
  pressure.39 A meta-analysis of three large pooled-data   studies 
with liraglutide showed a significant 2.7–4.5 mmHg   reduction 
in systolic blood pressure.40
Finally, treatment with liraglutide may have positive 
effects on plasma glucagon secretion, and does not impair 
the counterregulatory glucagon response to hypoglycemia in 
patients with T2DM.41 However, other studies26,36,44 failed to 
reproduce these findings.
Efficacy and safety
Encouraging preclinical and Phase I clinical pharmacology 
results with liraglutide led to larger Phase II trials in patients 
with T2DM, demonstrating that liraglutide is effective and 
well tolerated, both in monotherapy and in combination with 
oral antidiabetic drugs.
In a 12-week, double-blind, randomized, placebo-
  controlled trial with an open-label sulfonylurea comparator 
in 190 patients with T2DM, five fixed dosage groups of 
liraglutide were tested (0.045, 0.225, 0.45, 0.60, or 0.75 mg).42 
Treatment with the two highest dose of liraglutide reduced 
HbA1C significantly more than placebo (−0.70%, P = 0.0002, 
and −0.75%, P , 0.0001, respectively). Fifty-nine percent 
of patients completing the trial in the two highest dosage 
groups achieved HbA1C # 7%. In the 0.45 mg liraglutide 
dosage group, a statistically significant decrease in body 
weight (P = 0.0184) compared with placebo was noted. 
Mean β-cell function (measured by HOMA) was significantly 
higher in the 0.75 mg liraglutide group than in the placebo 
group (P = 0.0002). The proinsulin-to-insulin ratio decrease 
was statistically significant after treatment with 0.75 mg of 
liraglutide compared with placebo (P = 0.0244). Of the 135 
patients exposed to liraglutide, one in the 0.60 mg group 
experienced minor hypoglycemia. The number of patients 
with adverse events was comparable across the liraglutide 
groups and the placebo group. For gastrointestinal events 
(nausea), the incidence seemed to increase with increasing 
doses of liraglutide. Other events included diarrhea, vomiting, 
and constipation. Approximately two-thirds of these events 
were reported to resolve within 1–3 days.
Another 12-week, randomized, multicenter study com-
pared the same five doses of liraglutide with metformin.43 Drug Design, Development and Therapy 2010:4 submit your manuscript | www.dovepress.com
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HbA1C was maintained at a relatively stable level during 
treatment in the metformin group and in the 0.45 mg, 
0.6 mg, and 0.75 mg liraglutide groups. The two lowest 
liraglutide doses were not sufficient to maintain glycemic 
control. After 12 weeks, patients in the metformin group 
had a slight weight loss of −0.61% (P = 0.124 versus 
baseline), whereas the five liraglutide groups has a weight 
loss   ranging from −0.05% (0.045 mg, P = 0.825 versus 
baseline) to −1.87% (0.225 mg, P = 0.006, versus baseline). 
All   treatment groups, except for the lowest dose, showed a 
decrease in total body mass and total fat mass (measured by 
dual-energy X-ray absorptiometry scan). The study dem-
onstrated, except for the lowest liraglutide dose group, an 
increase in fasting serum insulin levels, with greater increases 
observed in the 0.75 mg dosage group; the same dosage 
group showed an increase in C-peptide levels that were sig-
nificantly different from the metformin group (P = 0.002). 
The   proportion of patients reporting adverse events with 
liraglutide treatment (52%–68%) was comparable with those 
treated with metformin (56%). The most frequent adverse 
event was injection site bruising, constipation, and diarrhea in 
the liraglutide group. The frequency of injection site bruising 
was not different between the liraglutide groups (5.7%) and 
the metformin group (5.9%), which only received placebo 
injection, indicating that bruising was most likely caused by 
the injection, rather than the trial medication. Five subjects 
(2.8%) in the liraglutide groups reported minor hypoglycemic 
events. There was no increase in the frequency of hypogly-
cemia as compared with metformin. No subjects showed a 
positive test for antibodies against liraglutide.
Nauck et al44 evaluated 144 T2DM patients on metformin 
treatment in a five-week study where patients were 
randomized to receive metformin plus liraglutide, liraglutide 
or metformin, or metformin plus glimepiride (open-label). 
The dose of liraglutide in the study was increased weekly 
from 0.5 mg to 2 mg. Adding on liraglutide to existing 
metformin therapy resulted in a 3.9 mmol/L decrease in 
fasting plasma glucose in favor of liraglutide treatment 
(P , 0.0001), whereas switching subjects from metformin 
to liraglutide monotherapy gave an additional 1.4 mmol/L 
reduction (P = 0.011). HbA1C lowered after treatment with 
metformin plus liraglutide compared with metformin alone 
(0.8%, P , 0.001). β-cell function (measured by HOMA) 
was significantly increased for metformin plus liraglutide ver-
sus metformin plus glimepiride (13.0%, P = 0.014), and for 
liraglutide versus metformin therapy (28.7%, P , 0.0001). 
Liraglutide monotherapy increased HOMA compared with 
metformin therapy (3.3%, P = 0.0001). After treatment, body 
weight had significantly decreased from baseline by 2.2 kg 
and 2.1 kg in the groups receiving liraglutide combination 
and monotherapy, respectively, and significantly by 1.7 kg 
on metformin monotherapy, with a significant difference in 
body weight reduction between the metformin plus liraglutide 
group compared with metformin plus glimepiride group 
(−2.9 kg, P , 0.0001).
Vilsbøll et al39 evaluated the efficacy of liraglutide as 
monotherapy in T2DM patients. The study was double-
blind, randomized, and placebo-controlled using three doses 
of   liraglutide (0.65, 1.25, or 1.90 mg). After 14 weeks of 
treatment, the HbA1C changes in the liraglutide groups com-
pared with placebo were −1.74%, P , 0.0001; −1.69%, 
P , 0.0001; and −1.27%, P , 0.0001, for the 1.90, 1.25, and 
0.65 mg doses, respectively. The proportion of patients reach-
ing HbA1C , 7% was 46% (1.90 mg), 48% (1.25 mg), 38% 
(0.65 mg), and 5% (placebo) in the four groups.   Glycemic 
control was associated with a decrease in body weight in all 
treatment groups, with a maximum estimated weight loss 
of 2.99 kg in the 1.90 mg liraglutide group (P = 0.0390). 
The median change from baseline in proinsulin-to-insulin 
ratio was significant for all three liraglutide groups versus 
placebo (P = 0.0111, P = 0.0062, and P = 0.0218 for the 
1.90, 1.25, and 0.65 mg doses, respectively). In addition, 
there was a significant lowering in fasting glucagon con-
centrations in the 1.90 mg liraglutide group compared with 
placebo (P = 0.0497). Systolic blood pressure decreased 
significantly in all treatment groups compared with placebo 
(−7.9 mmHg, P = 0.0023; −5.2 mmHg, P = 0.0417; 
−7.4 mmHg, P = 0.0041 in the 1.90, 1.25, and 0.65 mg 
groups, respectively), but the drop of 2–3 mmHg in the 
diastolic blood pressure in all groups was not statistically 
significant. Lipid parameters were also measured, but only 
triglyceride levels decreased compared with placebo (−22%, 
P = 0.0110; −15%, P = 0.0854; −19%, P = 0.0303 in the 1.90, 
1.25, and 0.65 mg groups, respectively). The proportions 
of patients reporting a gastrointestinal adverse event were 
37%, 29%, 38%, and 23% of patients treated with liraglutide 
1.90 mg, 1.25 mg, 0.65 mg, and placebo, respectively, with 
a higher event rate reported at the highest dose in the com-
parison with placebo (P , 0.05). Nausea seemed somewhat 
higher in the 1.90 mg and 0.65 mg groups. Only four of 123 
liraglutide-treated patients withdrew from the study because 
of gastrointestinal adverse events. The incidence of gastro-
intestinal adverse events decreased over time. No major or 
minor hypoglycemic episodes were reported. There were no 
treatment-related effects on induction of antibodies and no 
thyroid ultrasonographic changes.Drug Design, Development and Therapy 2010:4 submit your manuscript | www.dovepress.com
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There were no clinically relevant changes reported in vital 
signs, electrocardiographic parameters, physical examination, 
or safety laboratory parameters (hematology, biochemistry, 
and urinalysis) in any of the above studies.39,42–44
The first comparison between liraglutide and a 
DDP-4 inhibitor was in a parallel-group, open-label, 
multicenter trial, in which 658 patients with T2DM with 
inadequate glycemic control (HbA1C 7.5%–10%) on met-
formin were randomized to receive 1.2 mg or 1.8 mg of 
subcutaneous liraglutide once daily, or 100 mg oral sitagliptin 
once daily for 26 weeks.45 Mean decreases in HbA1C from 
baseline were −1.50% for 1.8 mg liraglutide, −1.24% for 
1.2 mg liraglutide, and −0.90% for sitagliptin (P , 0.0001 
between both the liraglutide and sitagliptin groups). Mean 
decreases in fasting plasma glucose were −2.14 mmol/L for 
1.8 mg liraglutide, −1.87 mmol/L for 1.2 mg liraglutide, 
and −0.83 mmol/L for sitagliptin (P , 0.0001 between both 
the liraglutide and sitagliptin groups). Mean weight loss 
was −3.38 kg for 1.8 mg liraglutide, −2.86 kg for 1.2 mg 
liraglutide, and −0.96 kg for sitagliptin (P , 0.0001 between 
both the liraglutide and sitagliptin groups). In assessment 
of β-cell function by HOMA, C-peptide concentration, 
and proinsulin-to-insulin ratio, both liraglutide doses were 
associated with improvement compared with sitagliptin. 
Changes in the lipid profile between liraglutide and sitagliptin 
were not significant, except for total cholesterol reduction that 
was greater with liraglutide 1.8 mg compared with sitagliptin 
(P = 0.0332). When comparing with sitagliptin, liraglutide 
1.8 mg and 1.2 mg caused a higher proportion of nausea, 
but this was transient (∼13 days). One patient on liraglutide 
1.2 mg had a major hypoglycemic episode (3.6 mmol/L). 
Minor hypoglycemic episodes were reported with similar 
frequency in all groups. One thyroid problem (reported as a 
formation in the thyroid gland) in a patient on 1.2 mg lira-
glutide was classified as a serious adverse event, but histology 
showed no signs of malignancy. Changes from baseline in 
serum calcitonin concentrations were similar across groups. 
No pancreatitis was reported.
In view of a weight benefit from treatment with 
liraglutide compared with other antidiabetic drugs, a study 
in obese individuals without T2DM using higher doses of 
liraglutide was performed.46 Obese subjects (body mass index 
30–40 kg/m2) were randomly assigned to receive liraglutide 
(1.2 mg, 1.8 mg, 2.4 mg, or 3.0 mg by subcutaneous injection 
once a day), placebo (also subcutaneously), or orlistat (120 mg 
three times a day orally). The trial was therefore masked 
for liraglutide or placebo treatment (but not the dose), and 
open-label for orlistat treatment. The estimated mean weight 
loss in the intention-to-treat population from randomization 
to week 20 was significantly greater with   liraglutide at all 
doses than with placebo (−2.8 kg), and was dose-dependent 
(−4.8 kg, −5.5 kg, −6.3 kg, −7.2 kg, for 1.2 mg, 1.8 mg, 
2.4 mg, and 3.0 mg doses, respectively). Sixty-one percent of 
individuals in the liraglutide treatment groups lost more than 
5% of their baseline weight, which was significantly more than 
that in the placebo group (P # 0.0001). Furthermore, more 
individuals treated with liraglutide 3.0 mg lost more than 5% 
baseline weight than those treated with orlistat (76% versus 
44%, P , 0.0001). The proportion of patients with metabolic 
syndrome at week 20 decreased by more than 60% in those 
treated with liraglutide 2.4 mg and 3.0 mg. Mean HbA1C in 
individuals treated with liraglutide was slightly reduced com-
pared with that in individuals on placebo and orlistat at week 
20; the reduction seemed to be dose-dependent, ranging from 
0.14% in the 1.2 mg group to 0.24% in the 3.0 mg dose group. 
Median β-cell function (as assessed by HOMA) decreased on 
placebo and orlistat treatment by 17% and 21%, respectively, 
but increased on liraglutide treatment by 5%–24%. The most 
common adverse events with liraglutide were nausea and 
vomiting, which occurred seven times more frequently with 
liraglutide 2.4 mg and 3.0 mg than with placebo. This was 
mostly transient and of mild or moderate intensity, and the 
frequency increased with dose. Most nausea events (80%) 
developed within the first four weeks of the trial during dose 
titration. Psychiatric disorders (insomnia, depressed mood, 
nervousness) were slightly more frequent in subjects treated 
with liraglutide 2.4 mg and 3.0 mg than in those on placebo. 
Serum calcitonin concentrations were measured, but no sig-
nificant effect was noted.
LEAD trials
Finally, a comprehensive Phase III evaluation consisting of 
six randomized clinical trials was developed. The LEAD 
(Liraglutide Effect and Action in Diabetes) program involved 
6500 subjects seen at 600 sites in 41 countries worldwide, of 
whom 4445 received liraglutide. The aim of these trials was 
to evaluate the efficacy and safety of liraglutide as mono-
therapy and in combination with other antidiabetic drugs and 
insulin (see Table 1).
LEAD 147 was a 26-week, five-arm randomized trial 
testing the effect of three doses of liraglutide (0.6, 1.2, and 
1.8 mg) added to glimepiride 4 mg/day in comparison with 
the same dose of glimepiride in combination with placebo 
or rosiglitazone 4 mg/day. At the end of the study, HbA1C 
levels were significantly more reduced in all liraglutide 
groups (−0.6%, −1.08%, and −1.13% for the 0.6, 1.2, and Drug Design, Development and Therapy 2010:4 submit your manuscript | www.dovepress.com
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1.8 mg doses, respectively) than with the placebo (+0.23%) or 
rosiglitazone (−0.44%) groups (P , 0.0001). The estimated 
proportion of subjects treated with either liraglutide 1.2 mg 
or 1.8 mg reaching HbA1C target was substantially greater 
compared with either placebo (P , 0.0001) or rosiglitazone 
(P # 0.0003), with more patients reaching HbA1C , 7.0% 
with liraglutide 1.8 mg compared with 1.2 mg (P = 0.018). 
All doses of liraglutide decreased fasting plasma glucose 
more than did placebo (P , 0.0001), while only liraglutide 
1.2 mg or 1.8 mg produced greater reductions than rosiglita-
zone. Changes in body weight were minor in all liraglutide 
and placebo groups, compared with the 2.1 kg increase in the 
rosiglitazone group. Reductions in the proinsulin-to-insulin 
ratio were greater with both liraglutide 1.2 mg and 1.8 mg 
compared with either rosiglitazone or placebo (P # 0.02). 
HOMA (β-cell function) increased with liraglutide (1.8 mg 
or 1.2 mg) compared with rosiglitazone (P , 0.05), while 
this increase was only different from placebo with liraglutide 
1.2 mg (P = 0.01). Changes in blood pressure and heart rate 
were not significant among groups.
LEAD 248 was a 26-week, placebo-controlled, double-
blind, five-arm, randomized trial testing the effect of three 
doses of liraglutide (0.6, 1.2, and 1.8 mg) added to metformin 
1 g twice daily as compared with the same dose of metformin 
in combination with placebo or glimepiride 4 mg/day. In 
comparison with placebo, HbA1C levels decreased signifi-
cantly more with liraglutide 0.6 mg (−0.8%), 1.2 mg (−1.1%), 
and 1.8 mg (−1.1%). The HbA1C target (7.0%) was achieved 
by significantly more subjects in the 1.8 mg liraglutide group 
than in the 1.2 mg liraglutide group (42.4% versus 35.3%, 
P = 0.0265). The decreases in fasting plasma glucose from 
baseline for the liraglutide groups (−1.1, −1.6, and 1.7 mmol/L 
for 0.6, 1.2, and 1.8 mg, respectively) were significantly 
greater than the increase observed for the placebo group 
(+0.4 mmol/L, P , 0.0001), but were similar to the decrease 
observed for the glimepiride group (−1.3 mmol/L). Weight 
loss was dose-dependent in the liraglutide treatment groups 
(1.8 ± 0.2, 2.6 ± 0.2, and 2.8 ± 0.2 kg for 0.6, 1.2, and 1.8 mg, 
respectively) and was significantly different (P , 0.0001) 
from the weight gain in the glimepiride group (1.0 ± 0.2 kg). 
Weight losses in the 1.2 mg and 1.8 mg liraglutide groups 
were also significantly greater (P # 0.01) than the weight 
loss in the placebo group (1.5 ± 0.3 kg). Decreases in the 
proinsulin-to-insulin ratio from baseline for the liraglutide 
groups were comparable with those in the glimepiride group 
and were significantly different (P , 0.0001) from those in 
the placebo group. The liraglutide groups had improvements 
in HOMA (β-cell function) of 63, 70, and 71% for the 0.6, 
1.2, and 1.8 mg liraglutide groups, respectively. The 1.2 mg 
and 1.8 mg liraglutide groups had significant reductions in 
systolic blood pressure of 2–3 mmHg compared with an 
increase of 0.4 mmHg observed in the glimepiride group 
(treatment difference compared with glimepiride: 1.2 mg 
liraglutide, −3.2 mmHg, P = 0.0128; 1.8 mg liraglutide, 
−2.7 mmHg, P = 0.0467).
An extension of the LEAD 2 trial with an 18-month 
open-label period where all patients were maintained on 
their randomized therapy was done to investigate treatment 
satisfaction obtained using a validated questionnaire.49 All 
the liraglutide groups showed improved overall satisfac-
tion from baseline, which was significantly greater than for 
metformin (P , 0.05), but comparable with glimepiride 
in combination with metformin. All the liraglutide groups 
were more satisfied with their “current treatment” and more 
likely to “continue” versus the metformin group after 26 and 
78 weeks (P , 0.05). Moreover, the liraglutide 1.2 mg and 
1.8 mg groups were “more likely to recommend to others” 
versus the metformin group (P , 0.05).
LEAD 350 was a 52-week randomized trial comparing 
liraglutide (0.8, 1.2, 1.8 mg) and glimepiride 8 mg/day. 
In comparison with glimepiride, HbA1C levels decreased 
  significantly more with liraglutide 1.2 mg (−0.33%, 
Table 1 Liraglutide effects and actions in diabetes studies
Study HbA1c % 
(∆ from baseline)
% with 
HbA1c # 7%
% with 
HbA1c # 6.5%
Body weight, kg  
(∆ from baseline)
SBP, mmHg  
(∆ from baseline)
Lipids, mmol/L  
(∆ from baseline)
LeAD-1 −1.1 42 21 −0.2 #−2.8 ND
LeAD-2 −1.0 42 25 −2.8 −2 to −3  ND
LeAD-3 −1.14 51 38 −2.5 −3.6 ND
LeAD-4 −1.5 54 36 −2 −5.6 TC: −0.20; LDL−C: −0.23; 
HDL–C: −0.04; TG: −0.32
LeAD-5 −1.3 52 37 −1.8 ND ND
LeAD-6 −1.12 54 35 −3.2 −2.5  TC: −0.20; LDL−C: −0.44; 
HDL–C: −0.04; TG: −0.41
Abbreviations: LeAD, liraglutide effects and actions in diabetes; HbA1c, hemoglobin A1c; ND, no data reported; NS, not significant; SBP, systolic blood pressure; TC, total 
cholesterol; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; TG, triglycerides.Drug Design, Development and Therapy 2010:4 submit your manuscript | www.dovepress.com
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P = 0.0014) and 1.8 mg (−0.62%, P , 0.0001). The   reduction 
with liraglutide 1.8 mg was significantly greater than that with 
1.2 mg (−0.29%, P = 0.0046). Participants previously treated 
with diet and exercise had greater decreases in HbA1C than 
did those who switched from an oral antidiabetic drug to lira-
glutide. At the end of the study, 28% of participants treated 
with liraglutide 1.2 mg and 38% treated with liraglutide 
1.8 mg reached the target HbA1C of 6.5% or less, compared 
with 16% in those on glimepiride (P = 0.0025 and P , 0.001 
for liraglutide 1.2 mg and 1.8 mg, respectively). Overall, 
compared with 28% in the glimepiride group, 43% of par-
ticipants treated with liraglutide 1.2 mg (P = 0.0007) and 
51% on liraglutide 1.8 mg (P , 0.0001) reached the target 
HbA1C of less than 7%. A greater proportion of participants 
in the liraglutide groups achieved the fasting plasma glucose 
target (5.0–7.2 mmol/L) than in the glimepiride group (37.6% 
and 41.4% versus 22.2% for liraglutide 1.2 mg and 1.8 mg 
versus glimepiride group, respectively, P # 0.0001). Treat-
ment with liraglutide was also associated with weight loss, 
whereas the glimepiride group presented weight gain. Insulin 
resistance (measured by HOMA) was reduced by 0.65% in 
the liraglutide 1.2 mg group and 1.35% in the 1.8 mg group, 
but increased in the glimepiride group (P = 0.0249 and 
P = 0.0011 for liraglutide 1.2 mg and 1.8 mg, respectively). 
The proinsulin-to-insulin ratio and β-cell function showed 
no significant differences between treatments.
The double-blind period was followed by an open-label, 
two-year extension, involving 73% of the patients who had 
completed the one-year follow-up. Results showed that the 
greater benefit of liraglutide on metabolic control and body 
weight as compared with glimepiride was maintained after 
two years, with a lower risk of hypoglycemia.51
Patient-reported outcome assessments were performed as 
part of the LEAD 3 trial.52 The battery of scales compromised 
77 self-administered questions. Patient weight assessment 
was more favorable with liraglutide 1.8 mg (P = 0.002), 
and 52% were less likely to feel overweight. Mean weight 
concerns were less with liraglutide than with glimepiride 
(P , 0.0001 and P , 0.001 for 1.2 and 1.8 mg liraglutide, 
respectively). Mean mental and emotional health and general 
perceived health assessments improved more with liraglutide 
1.8 mg than with glimepiride (P = 0.012 and P = 0.033, 
respectively).
LEAD 453 was a 26-week, placebo-controlled, double-
blind, randomized, parallel-group trial testing the effect of 
two doses of liraglutide (1.2 and 1.8 mg) added to metformin 
1 g twice daily and rosiglitazone 4 mg/day compared with 
the same dose of metformin and rosiglitazone in combination 
with placebo. Mean HbA1C levels decreased significantly 
more in the liraglutide groups than in the placebo group 
(−0.9% and −1.1% for liraglutide 1.2 and 1.8 mg, respec-
tively, P , 0.0001). At the end of the study, 57.5% and 
53.7% of subjects in the 1.2 and 1.8 mg liraglutide groups, 
respectively, had an HbA1C , 7%, compared with 28.1% 
in the placebo group, with 37.3% and 36.2%, respectively, 
reaching #HbA1C of 6.5% compared with 14.4% on placebo. 
The decreases in fasting plasma glucose from baseline for 
the liraglutide groups (−2.2 mmol/L and −2.4 mmol/L for 
1.2 mg and 1.8 mg liraglutide, respectively) were signifi-
cantly greater than the decrease observed in the placebo group 
(−0.4 mmol/L, P , 0.0001). Weight loss was observed in the 
liraglutide-treated groups (1.0 ± 0.3 and 2.0 ± 0.3 kg from 
baseline for 1.2 mg and 1.8 mg liraglutide, respectively), 
and was significantly different (P , 0.0001) from the weight 
gain in the placebo group (0.6 ± 0.3 kg). The weight loss in 
the 1.8 mg liraglutide group was significantly greater than in 
the 1.2 mg liraglutide group (P = 0.011). The 1.2 and 1.8 mg 
liraglutide groups had significant reductions in mean systolic 
blood pressure compared with the placebo group (1.2 mg 
liraglutide P , 0.0001; 1.8 mg liraglutide P = 0.0009). 
Minor but statistically significant increases in pulse rate were 
observed in the liraglutide-treated groups versus placebo 
(P = 0.0071 and P = 0.0001, respectively, for 1.2 mg and 
1.8 mg). The decrease in the proinsulin-to-insulin ratio and 
increase in C-peptide concentration from baseline for the lira-
glutide groups were significant (P , 0.05 for both) compared 
with the placebo group. Both liraglutide treatment groups had 
significant improvement in β-cell function (P , 0.0001 for 
both groups versus placebo). Insulin resistance (measured by 
HOMA) was reduced in all three treatment groups, but was 
not significantly different between groups.
LEAD 554 was a 26-week, randomized, placebo-  controlled, 
double-blind, parallel-group trial testing the effect of 1.8 mg of 
liraglutide added to metformin 1 g twice daily plus glimepiride 
2–4 mg/day in comparison with the same dose of metformin 
and glimepiride with placebo or insulin glargine. After 
26 weeks of treatment, the HbA1C reduction from baseline 
with liraglutide was 1.33%, 0.24% with placebo, and 1.09% 
with insulin glargine (treatment differences for liraglutide 
versus placebo (−1.09%, P , 0.0001 and liraglutide versus 
insulin glargine −0.24%, P = 0.0015). The reduction in mean 
fasting plasma glucose in the liraglutide group, and the likeli-
hood of achieving targets (5–7.2 mmol/L) was significantly 
superior compared with the placebo group (P , 0.0001) but 
not versus the insulin glargine group. The mean weight loss 
from baseline of 1.8 kg achieved in the liraglutide group was Drug Design, Development and Therapy 2010:4 submit your manuscript | www.dovepress.com
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significantly superior to that in the placebo group (weight 
  difference of −1.39 kg, P = 0.0001). Weight increased by 
1.6 kg with insulin glargine, resulting in a mean treatment 
difference of −3.43 kg, P , 0.0001. Overall, weight loss was 
independent of nausea, although in the very small number of 
patients with sustained nausea, there seemed to be a greater 
weight loss (−3.2 kg). The proinsulin-to-C-peptide ratio 
showed a significant improvement in the liraglutide group 
compared with the insulin glargine group (P = 0.0019) and 
the placebo group (P , 0.0001). A significant reduction 
in systolic blood pressure was observed with liraglutide 
(−4.0 mmHg) compared with insulin glargine (0.54 mmHg 
increase; treatment difference −4.51 mmHg, P = 0.0001), but 
not in comparison with placebo.
Blonde and Russell-Jones summarized the safety of 
  liraglutide during LEAD 1–5 studies.55 Throughout the trials, 
liraglutide was generally well tolerated; most adverse events 
reported were mild to moderate in severity. Gastrointestinal 
events were most frequently reported with liraglutide 
monotherapy and combination therapy and were often 
dose-related; 29.3% of patients receiving 1.8 mg liraglutide 
reported nausea. However, this symptom tended to decrease 
in frequency after four weeks in each trial. Serious adverse 
events were uncommon. In the LEAD 5 trial, patients treated 
with insulin glargine or placebo reported a 7% frequency of 
serious adverse events in comparison with 4% on liraglutide 
therapy. Few minor and major hypoglycemic episodes have 
been reported across the LEAD studies. As monotherapy, 
no major hypoglycemia incidents were reported, and 8% 
of patients treated with liraglutide 1.8 mg reported minor 
hypoglycemia (plasma glucose ,3.1 mmol/L). Only one 
major hypoglycemic episode (blood glucose = 3.0 mmol/L) 
was reported when liraglutide was used in combination with 
glimepiride. No major hypoglycemia was reported when 
liraglutide was used in combination with metformin. The 
proportion of subjects experiencing minor hypoglycemia 
across a 26-week treatment period with liraglutide 1.8 mg in 
combination with glimepiride was 8.1%, significantly greater 
than the proportion of subjects on rosiglitazone in combina-
tion with glimepiride (4.3%, P = 0.0065). The incidence of 
minor hypoglycemia was lower when liraglutide was used 
in combination with metformin (∼3%).
Antibodies to liraglutide were found in 9%–13% of 
subjects treated with liraglutide in the LEAD 1study; 4.1% 
and 6.7% of subjects treated with 1.2 and 1.8 mg liraglutide, 
respectively, at the end of LEAD 4; and in 9.8% of patients in 
the liraglutide group in LEAD 5. No significant   differences in 
calcitonin levels were found between the liraglutide groups 
and comparators in the LEAD 2, 3, and 5 studies. There 
was a significant increase in calcitonin levels for the 1.2 mg 
liraglutide group versus placebo group (P = 0.022), but 
not with the 1.8 mg liraglutide group in the LEAD 4 study 
(although all levels were in the normal range).47,48,50,53,54
LEAD 6 was the first study that compared two GLP-1 
  analogs.56 This was a 26-week, randomized, open-label trial 
testing the effect of liraglutide 1.8 mg once daily versus 
exenatide 10 µg twice daily in combination with metformin 
1 g twice daily and/or glimepiride 2–4 mg/day. Patients 
treated with liraglutide showed a reduction in HbA1C of 1.12%, 
  compared with a reduction of 0.79% in the exenatide group 
(P , 0.0001), and more patients achieved an HbA1C , 7% in the 
liraglutide group (54% versus 43%, respectively, P = 0.0015). 
Liraglutide caused a greater reduction in fasting plasma 
glucose (−1.61 mmol/l versus −0.60 mmol/L of exenatide, 
P , 0.0001). Weight loss was similar in the two groups, 
and was approximately 3 kg. Increases in fasting plasma 
insulin (P = 0.0355) and β-cell function (P , 0.0001) were 
significantly greater for the liraglutide group than for the 
exenatide group.   Treatment differences for fasting C-peptide 
and proinsulin-to-insulin ratio were not significant. Fasting 
glucagon and blood pressure decreased with both treatments. 
Reduction of   triglyceride (P = 0.0485) and free fatty acid 
(P = 0.014) values were significantly greater in the liraglutide 
group than in the exenatide group.
Despite an overall lower reporting of adverse events in 
the liraglutide group than the exenatide group, the liraglutide 
group had more serious (5.1% versus 2.6%) and severe 
(7.2% versus 4.7%) adverse events. The most frequent 
severe adverse events were dyspepsia in the liraglutide group 
and nausea in the exenatide group. Although the incidence 
of nausea was similar initially, it was less persistent with 
liraglutide. No major hypoglycemia occurred with liraglutide. 
The proportion of patients who had minor hypoglycemia was 
lower with liraglutide than with exenatide (26% versus 34%, 
respectively). Small decreases in calcitonin levels occurred 
during the trial in both groups. Heart rates increased slightly 
in both treatment groups, but were significantly greater for 
liraglutide (P = 0.0012).
After 26 weeks, patients continued into a nonrandomized 
14-week extension;57 all exenatide patients were switched to 
liraglutide 0.6 mg then escalated to 1.8 mg. Patients originally 
randomized to liraglutide 1.8 mg continued on this dose. 
Mean HbA1C further decreased from 7.2% at week 26 to 6.9% 
at week 40 (P , 0.0001) after switching from exenatide to 
liraglutide, but remained similar with continued liraglutide 
(7.0%–6.9%). Further reductions in fasting plasma glucose, Drug Design, Development and Therapy 2010:4 submit your manuscript | www.dovepress.com
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body weight, and systolic blood pressure (all P , 0.0001) 
occurred, while the HOMA (β-cell function) increased 
(P = 0.0001) after switching from exenatide to liraglutide. In 
patients continuing liraglutide, reductions in fasting plasma 
glucose (P = 0.0973), body weight (P = 0.0089), and systolic 
blood pressure (P = 0.0128) occurred. Nausea and diarrhea 
occurred in 3.2% of patients switching from exenatide to 
liraglutide and in 1.5% of those continuing liraglutide. One 
major hypoglycemic episode occurred in a patient continuing 
liraglutide. Calcitonin levels remained at the lower level of 
the normal range and did not differ between the groups. No 
cases of medullary thyroid carcinoma or pancreatitis were 
reported during the extension.
Other safety issues
In a two-year mouse and rat carcinogenicity study, liraglutide 
resulted in treatment-related proliferative changes in C-cells 
of the thyroid gland. These changes ranged from focal 
hyperplasia to benign and malignant neoplasia, and were 
dose-dependent.58 The clinical relevance of this finding is 
unknown. Moreover, five cases of papillary thyroid carci-
noma have been reported in clinical trials in patients treated 
with liraglutide compared with one case in a comparator 
treatment group.59
According to Novo Nordisk,60 because of the uncertain 
relevance of the rodent C-cell tumor findings in humans, 
liraglutide should be prescribed only to patients for whom 
the potential benefits are considered to outweigh the 
potential risks. Liraglutide is contraindicated in patients 
with a personal or family history of medullary thyroid 
carcinoma and in patients with multiple endocrine neo-
plasia syndrome type 2. Based on the findings in rodents, 
monitoring with serum calcitonin or thyroid ultrasound 
was performed during clinical trials, but this may have 
increased the number of unnecessary thyroid surgeries. 
Liraglutide appears to be associated with a risk of acute 
pancreatitis, with seven cases in 3900 patients receiving 
liraglutide versus one case in a patient taking another 
diabetic drug.61
Conclusion
All liraglutide trials have demonstrated a consistent and 
  sustained reduction in HbA1C and fasting plasma glucose 
when the drug was used as monotherapy or added to other 
antidiabetic therapy. The advantages are its incretin effect, 
and the convenience of once-daily injection. The presence 
of antibodies was observed, but there were no indications 
in any of the liraglutide studies that antibody formation 
compromised efficacy. Patients should be counseled regarding 
risk and symptoms of thyroid tumors and acute pancreatitis. 
Liraglutide will acquire an important role, not only in T2DM 
treatment, but also in preservation of β-cell function, if the 
data thus far are confirmed by long-term studies and post-
marketing surveillance. Furthermore, the reduction in HbA1C 
associated with the beneficial effects of liraglutide in insulin 
resistance, systolic blood pressure, and weight loss, as shown 
by the LEAD studies, could represent a significant probabil-
ity of prevention of diabetic complications and may reduce 
atherosclerotic cardiovascular events.
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